The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
Background. The aim of the study was to estimate the direct medical costs of metastatic colorectal cancer (mCRC) treated at the Institute of Oncology Ljubljana and to question the healthcare payment system in Slovenia.
Main Authors: | Mesti Tanja, Boshkoska Biljana Mileva, Kos Mitja, Tekavčič Metka, Ocvirk Janja |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2015-06-01
|
Series: | Radiology and Oncology |
Subjects: | |
Online Access: | https://doi.org/10.2478/raon-2014-0046 |
Similar Items
-
Cost-Effectiveness Analysis of Regorafenib versus Other Third-Line Treatments for Metastatic Colorectal Cancer
by: Zhong J, et al.
Published: (2024-06-01) -
The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018
by: Mesti Tanja, et al.
Published: (2023-03-01) -
Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
by: Bai L, et al.
Published: (2019-12-01) -
Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
by: Rebersek Martina, et al.
Published: (2019-03-01) -
Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
by: Matthew E. Pollard, et al.
Published: (2017-01-01)